Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tick-borne encephalitis vaccine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Tick-borne Encephalitis Vaccine | BIOLOGICAL | - |
Inclusion Criteria: Male and female children will be eligible for participation in this study if: * they are 1 year (from the 1st birthday) to 6 years (to the last day before the 6th birthday) old; * they are clinically healthy; * their legal representative understands the nature of the study, agr...
Tick-borne encephalitis vaccine is used for the prevention of Tick-borne Encephalitis, a viral infection transmitted by ticks. It is being developed as an investigational vaccine for this infectious disease indication.
Tick-borne encephalitis vaccine is being developed by Pfizer, Inc., which trades under the ticker PFE. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
Tick-borne encephalitis vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. Two Phase 2 trials have been completed to assess its safety and immunogenicity.
Tick-borne encephalitis vaccine has been studied in two completed Phase 2 trials: NCT00161772, a dose-finding study in healthy volunteers aged 1 to 6 years, and NCT00161798, a dose-finding study in healthy volunteers aged 6 to 16 years. Both trials were conducted in Germany and Austria.
Tick-borne encephalitis vaccine is classified as a monoclonal antibody modality, though it is being developed as a vaccine for Tick-borne Encephalitis. It is administered to healthy volunteers in clinical trials to evaluate its safety and immunogenicity.